Former FDA counsel: Off-label marketing ban in jeopardy

11/3/2011 | Wall Street Journal, The

Drugmakers have filed a friends-of-the-court brief asserting that marketing drugs for unapproved uses is protected free speech. FDA rules prohibiting off-label marketing are meant to protect patients, says Thomas W. Abrams, director of the FDA's Division of Drug Marketing, Advertising and Communications. Former FDA chief counsel Richard Cooper said a Supreme Court ruling in June on pharmacy records could put the FDA's ban on off-label marketing "in some jeopardy."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL